kidney neoplasms/tyrosine

Linkul este salvat în clipboard

Alegeți tipul de sortare

Pagină 1 din 494 rezultate

Enhanced expression of membrane phosphoproteins tyrosine phosphorylation in estrogen-induced kidney tumors.

Numai utilizatorii înregistrați pot traduce articole

We demonstrate for the first time that the expression of tyrosine containing membrane phosphoproteins is elevated in estrogen-induced kidney tumors, which is evident from both the types of experiments, i.e., alkali-resistant phosphorylation of membrane proteins and immunoprecipitation of tyrosine

Regulation of glycolipid sulfotransferase by tyrosine kinases in human renal cancer cells.

Numai utilizatorii înregistrați pot traduce articole

Glycolipid sulfotransferase activity in a human renal cancer cell line, SMKT-R3, is enhanced by the action of growth factors such as EGF, TGF-alpha and HGF, whose receptors possess tyrosine kinase domains. We investigated whether tyrosine kinases are involved in the regulation of the

[Complete response to tyrosine kinase inhibitors in metastatic renal cancer. Report of four cases].

Numai utilizatorii înregistrați pot traduce articole

UNASSIGNED To describe the complete responses in our patients with metastatic renal cancer treated with tyrosine kinase inhibitors. METHODS Between June 2007 and December 2014 we treated in our department 43 patients with metastatic renal cancer with antiangiogenic drugs. RESULTS 9.3% (4/43) of the

Learning curve for the management of tyrosine kinase inhibitors as the first line of treatment for patients with metastatic renal cancer.

Numai utilizatorii înregistrați pot traduce articole

OBJECTIVE To analyse the learning curve for the management of tyrosine kinase inhibitors as the first line of treatment for patients with metastatic renal cancer. METHODS We evaluated 32 consecutive patients treated in our department for metastatic renal cancer with tyrosine kinase inhibitors

Differential expression of SHP2, a protein-tyrosine phosphatase with SRC homology-2 domains, in various types of renal tumour.

Numai utilizatorii înregistrați pot traduce articole

SHP2, a widely distributed protein-tyrosine phosphatase with src homology-2 (SH2) domains, is highly expressed in the brain and may play a role in synaptic communications or cellular proliferation. In this study, we examined SHP2 protein expression in 110 renal cell tumours of various histological

Receptor tyrosine kinase inhibition suppresses growth of pediatric renal tumor cells in vitro.

Numai utilizatorii înregistrați pot traduce articole

OBJECTIVE Children who undergo standard therapy for renal tumors are at an increased risk for treatment sequelae such as congestive heart failure, abnormal trunk development, and secondary malignancies. Therefore, research on the use of novel chemotherapeutic agents with fewer side effects is

Association between tyrosine-kinase inhibitor induced hypertension and treatment outcomes in metastatic renal cancer

Numai utilizatorii înregistrați pot traduce articole

Background: Tyrosine-kinase inhibitor (TKI) drugs have been considered first line treatment for metastatic renal cell cancer (RCC) for over a decade. TKI-induced hypertension is a common adverse-event in patients treated for metastatic

Limitations to the Therapeutic Potential of Tyrosine Kinase Inhibitors and Alternative Therapies for Kidney Cancer.

Numai utilizatorii înregistrați pot traduce articole

Background: Renal cell carcinomas (RCCs) are the most common primary renal tumor. RCCs have a high rate of metastasis and have the highest mortality rate of all genitourinary cancers. They are often diagnosed late when metastases have developed, and these metastases are difficult to treat

Effect of the UK postcode lottery on survival of patients with metastatic renal cancer: an audit of outcomes in patients with metastatic renal cancer suitable for treatment with tyrosine kinase inhibitors.

Numai utilizatorii înregistrați pot traduce articole

OBJECTIVE To determine whether primary care trusts' agreement or refusal to fund sorafenib or sunitinib affects outcomes for patients with metastatic renal cell carcinoma. METHODS This retrospective audit was conducted in a tertiary referral centre for urological cancer. Requests to prescribe drugs

Tyrosine kinase inhibitors and anti-angiogenic therapies in kidney cancer.

Numai utilizatorii înregistrați pot traduce articole

Renal cell carcinoma (RCC) is a heterogeneous disease as reflected in its presentation and clinical course, pathological subtypes, nuclear grades and molecular biology. Emerging data indicate that renal tumors express a variety of molecular tumor markers and unique patterns of gene expression.

Emerging tyrosine kinase inhibitors for the treatment of renal cancer.

Numai utilizatorii înregistrați pot traduce articole

BACKGROUND Since both cytotoxic and cytokine therapy were not able to improve the prognosis of advanced renal cell carcinoma (RCC), this tumor has been a good model for the development of new biological agents in the past decade. Five VEGF receptor (VEGFR) and two mammalian target of rapamycin

Predictive factor and antihypertensive usage of tyrosine kinase inhibitor-induced hypertension in kidney cancer patients.

Numai utilizatorii înregistrați pot traduce articole

Hypertension (HT) is the common adverse event associated with vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKI). The present study was performed to identify the predictive factors of TKI-induced HT and to determine the classes of antihypertensive agents (AHTA) that

Management of renal cancer in the tyrosine kinase inhibitor era: a view from 3 years on.

Numai utilizatorii înregistrați pot traduce articole

In the last 3 years there has been a dramatic increase in the treatment options for patients with metastatic renal cancer. In addition to the cytokines interferon and interleukin 2, recently approved agents include sorafenib, sunitinib, temsirolimus and bevacizumab. A plethora of agents that are

Tyrosine receptor kinase B silencing inhibits anoikis‑resistance and improves anticancer efficiency of sorafenib in human renal cancer cells.

Numai utilizatorii înregistrați pot traduce articole

Renal cell carcinoma (RCC) is the most common solid neoplasm of adult kidney, and the major treatment for metastatic RCC (mRCC) is molecular targeted therapy. Sorafenib, as a multi-targeted tyrosine kinase inhibitor (TKI), has significantly improved clinical outcomes of mRCC patients. However,

Receptor tyrosine kinase-like orphan receptor 2 (Ror2) expression creates a poised state of Wnt signaling in renal cancer.

Numai utilizatorii înregistrați pot traduce articole

Expression of the receptor tyrosine kinase-like orphan receptor 2 (Ror2) has been identified in an increasing array of tumor types and is known to play a role as an important mediator of Wnt signaling cascades. In this study, we aimed to clarify Ror2 interactions with the Wnt pathways within the

Anterior
1
2
3
4
5
6
...
32
33
Următor →

Alăturați-vă paginii
noastre de facebook

Herbal & Natural Medicine

Cea mai completă bază de date cu plante medicinale susținută de știință

Funcționează în 55 de limbi
Cure pe bază de plante susținute de știință
Recunoașterea ierburilor după imagine
Harta GPS interactivă - etichetați ierburile în locație (în curând)
Citiți publicațiile științifice legate de căutarea dvs.
Căutați plante medicinale după efectele lor
Organizați-vă interesele și rămâneți la curent cu noutățile de cercetare, studiile clinice și brevetele

Tastați un simptom sau o boală și citiți despre plante care ar putea ajuta, tastați o plantă și vedeți boli și simptome împotriva cărora este folosit.
* Toate informațiile se bazează pe cercetări științifice publicate